We came across a bullish thesis on Syndax Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on SNDX. Syndax Pharmaceuticals, Inc.’s share was trading at $20.67 as of January 15th.
Phovoir/Shutterstock.com
Syndax Pharmaceuticals has transitioned into a commercial-stage biotech anchored by two first-in-class approved therapies, Revuforj (revumenib) and Niktimvo (axatilimab), each addressing areas of high unmet...
